Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Not Applicable

Completed

• Conditions: DIABETES MELLITUS, TYPE 2

• Registration Number: NCT02435693
• Lead Sponsor: TABREJ MUJAWAR

Brief Summary

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

1. To evaluate Pharmaceutical care program in Type2 diabetics.

2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

3. To study the prevalence of Type2 diabetics cases in Dhule.

4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.

7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.

8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.

9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.

10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Detailed Description

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Study Timeline

• Study Start: 2012-07
• Study First Submitted: 2015-02-07
• Study First Submitted QC: 2015-05-05
• Study First Posted: 2015-05-06
• Primary Completion: 2015-06
• Status Verified: 2015-11
• Study Completion: 2015-11
• Last Update Submitted: 2015-11-03
• Last Update Posted: 2015-11-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus of either
• Patients with HbA1c more than 7% and
• Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria

• Patient with end stage kidney disease.
• Patient with heart failure.
• Patient with chronic Diabetes problem and orthopedic problem

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded	24 weeks	Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose

Secondary Outcome Measures

Name	Time	Method
Quality of Life score	24 weeks	Quality of Life score

Trial Locations

Locations (1)

Tabrej Aj Mujawar; 🇮🇳 Dhule, Maharashtra, India